873055-90-4

Basic information

• Product Name: 1,3-DIAMINE-4-TRIFLUOROMETHOXYBENZENE
• Synonyms: 1,3-DIAMINE-4-TRIFLUOROMETHOXYBENZENE;4-(TRIFLUOROMETHOXY)BENZENE-1,3-DIAMINE;1,3-Diamino-4-(trifluoromethoxy)benzene
• CAS NO: 873055-90-4
• Molecular Formula: C₇H₇F₃N₂O
• Molecular Weight: 192.14
• Product Categories: Fluorine series
• Mol File: 873055-90-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1,3-DIAMINE-4-TRIFLUOROMETHOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-DIAMINE-4-TRIFLUOROMETHOXYBENZENE(873055-90-4)
• EPA Substance Registry System: 1,3-DIAMINE-4-TRIFLUOROMETHOXYBENZENE(873055-90-4)

Safety Data

• Hazardous Substances Data: 873055-90-4(Hazardous Substances Data)

Usage

General Description

1,3-diamine-4-trifluoromethoxybenzene is a chemical compound with the molecular formula C8H10F3NO. It is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound is also used in organic synthesis as a building block for making complex molecules. It has a trifluoromethoxy group attached to the benzene ring, which imparts unique chemical and physical properties to the compound. Overall, 1,3-diamine-4-trifluoromethoxybenzene is a versatile chemical that finds applications in various industries.

Upstream product

• 2822-50-6 3-nitro-4-(trifluoromethoxy)aniline 
• 655-07-2 2,4-dinitro-1-(trifluoromethoxy)benzene 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.